advertisement
Abstract #6511 Published in IGR 3-2
Neuroprotection in glaucoma. Where is the clinical evidence?
Haefliger IO; Pellanda N; Fleischhauer JC; Gekkieva M; Flammer JOphthalmologe 2001; 98: 564-567
BACKGROUND: Glaucoma is an optic neuropathy where retinal ganglion cells (RGC) are lost. It is postulated that this is due to apoptosis, a genetically regulated cell death mechanism that can potentially be modulated by drugs. METHODS: A non-exhaustive review of the literature related to the potential of neuroprotection to prevent RGC loss in glaucoma. RESULTS: There exists preclinical evidence, as well as rare observations in humans, suggesting that RGC could be lost by apoptosis in glaucoma. Potential stimuli that could trigger RGC apoptosis are interruption of axoplasmatic flow, generation of reactive oxygen species, nitric oxide-induced toxicity and glutamate-induced excitotoxicity. In animal models of glaucoma the possibility of preserving RGC loss by neuroprotective drugs is supported by many encouraging observations. However, as yet, no clinical studies have challenged this issue in humans. Only recently has such a clinical trial been initiated. CONCLUSIONS: The concept of neuroprotection in glaucoma makes sense, however, clinical evidence is still lacking. LA: German
Dr I.O. Haefliger, Labor okulare Pharmakol./Physiol., Universitäts-Augenklinik, Mittlere Strasse 91, 4012 Basel, Switzerland
Classification:
11.8 Neuroprotection (Part of: 11 Medical treatment)
